These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
474 related articles for article (PubMed ID: 10805063)
1. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Katoh M; Nakajima M; Shimada N; Yamazaki H; Yokoi T Eur J Clin Pharmacol; 2000; 55(11-12):843-52. PubMed ID: 10805063 [TBL] [Abstract][Full Text] [Related]
2. Inhibitory effects of azelastine and its metabolites on drug oxidation catalyzed by human cytochrome P-450 enzymes. Nakajima M; Ohyama K; Nakamura S; Shimada N; Yamazaki H; Yokoi T Drug Metab Dispos; 1999 Jul; 27(7):792-7. PubMed ID: 10383922 [TBL] [Abstract][Full Text] [Related]
3. Isoform selective inhibition and inactivation of human cytochrome P450s by methylenedioxyphenyl compounds. Nakajima M; Suzuki M; Yamaji R; Takashina H; Shimada N; Yamazaki H; Yokoi T Xenobiotica; 1999 Dec; 29(12):1191-202. PubMed ID: 10647906 [TBL] [Abstract][Full Text] [Related]
4. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Wen X; Wang JS; Neuvonen PJ; Backman JT Eur J Clin Pharmacol; 2002 Jan; 57(11):799-804. PubMed ID: 11868802 [TBL] [Abstract][Full Text] [Related]
5. Effect of nilvadipine, a dihydropyridine calcium antagonist, on cytochrome P450 activities in human hepatic microsomes. Niwa T; Shiraga T; Hashimoto T; Kagayama A Biol Pharm Bull; 2004 Mar; 27(3):415-7. PubMed ID: 14993813 [TBL] [Abstract][Full Text] [Related]
6. Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Cohen LH; van Leeuwen RE; van Thiel GC; van Pelt JF; Yap SH Biopharm Drug Dispos; 2000 Dec; 21(9):353-64. PubMed ID: 11523064 [TBL] [Abstract][Full Text] [Related]
7. Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4. Katoh M; Nakajima M; Yamazaki H; Yokoi T Pharm Res; 2000 Oct; 17(10):1189-97. PubMed ID: 11145223 [TBL] [Abstract][Full Text] [Related]
8. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509 [TBL] [Abstract][Full Text] [Related]
9. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863 [TBL] [Abstract][Full Text] [Related]
10. Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes. Hanioka N; Ozawa S; Jinno H; Tanaka-Kagawa T; Nishimura T; Ando M; Sawada Ji J Drug Metab Dispos; 2002 Apr; 30(4):391-6. PubMed ID: 11901092 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of human drug metabolizing cytochrome P450 by buprenorphine. Umehara K; Shimokawa Y; Miyamoto G Biol Pharm Bull; 2002 May; 25(5):682-5. PubMed ID: 12033517 [TBL] [Abstract][Full Text] [Related]
12. Effect of gamma-oryzanol on cytochrome P450 activities in human liver microsomes. Umehara K; Shimokawa Y; Miyamoto G Biol Pharm Bull; 2004 Jul; 27(7):1151-3. PubMed ID: 15256760 [TBL] [Abstract][Full Text] [Related]
13. Effect of probucol on cytochrome P450 activities in human liver microsomes. Umehara K; Shimokawa Y; Miyamoto G Biol Pharm Bull; 2002 Aug; 25(8):1112-4. PubMed ID: 12186421 [TBL] [Abstract][Full Text] [Related]
14. Development and Validation of a Higher-Throughput Cytochrome P450 Inhibition Assay with the Novel Cofactor-Supplemented Permeabilized Cryopreserved Human Hepatocytes (MetMax Human Hepatocytes). Palacharla VRC; Chunduru P; Ajjala DR; Bhyrapuneni G; Nirogi R; Li AP Drug Metab Dispos; 2019 Oct; 47(10):1032-1039. PubMed ID: 31375472 [TBL] [Abstract][Full Text] [Related]
15. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Eagling VA; Tjia JF; Back DJ Br J Clin Pharmacol; 1998 Feb; 45(2):107-14. PubMed ID: 9491822 [TBL] [Abstract][Full Text] [Related]
16. Effects of irsogladine on P450-isoform specific activities in human hepatic microsomes. Nakamura A; Tougou K; Kitazumi H; Yamada T; Honjou K; Nonaka K; Mukai H Arzneimittelforschung; 2006; 56(7):547-52. PubMed ID: 16927538 [TBL] [Abstract][Full Text] [Related]
17. Inhibitory Effects of Dimethyllirioresinol, Epimagnolin A, Eudesmin, Fargesin, and Magnolin on Cytochrome P450 Enzyme Activities in Human Liver Microsomes. Kim JH; Kwon SS; Jeong HU; Lee HS Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28468305 [TBL] [Abstract][Full Text] [Related]
18. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Yao HT; Chang YW; Lan SJ; Chen CT; Hsu JT; Yeh TK Life Sci; 2006 Nov; 79(26):2432-40. PubMed ID: 16978661 [TBL] [Abstract][Full Text] [Related]
19. In vitro inhibition of human cytochrome P450 enzymes by the novel atypical antipsychotic drug asenapine: a prediction of possible drug-drug interactions. Wójcikowski J; Danek PJ; Basińska-Ziobroń A; Pukło R; Daniel WA Pharmacol Rep; 2020 Jun; 72(3):612-621. PubMed ID: 32219694 [TBL] [Abstract][Full Text] [Related]
20. In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists. Taavitsainen P; Kiukaanniemi K; Pelkonen O Eur J Clin Pharmacol; 2000 May; 56(2):135-40. PubMed ID: 10877007 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]